133 assets in Sickle Cell Disease

Therapeutic assets addressing Sickle Cell Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Glutamine Sickle Cell Disease	Ain Shams University	P4	BBB (72)
Hydroxyurea Sickle Cell Disease	St. Jude Children's Research Hospital	P4	BB (71)
Crizanlizumab Sickle Cell Disease	Novartis Pharmaceuticals	P4	BB (70)
Nivestim Sickle Cell Disease	St. Jude Children's Research Hospital	P4	BB (70)
ARG Sickle Cell Disease	Tanta University	P3	BB (69)
Nepenthe Sickle Cell Disease	Oman Medical Speciality Board	P4	BB (69)
Cyclophosphamide Sickle Cell Disease	St. Jude Children's Research Hospital	P2/3	BB (67)
Deferasirox Sickle Cell Disease	Inova Health Care Services	P4	BB (67)
Busulfanum Sickle Cell Disease	St. Jude Children's Research Hospital	P2/3	BB (66)
Campath Sickle Cell Disease	Columbia University	P2/3	BB (65)
Famotidine Sickle Cell Disease	Bristol-Myers Squibb	P2/3	BB (65)
Medroxyprogesterone Sickle Cell Disease	University of Pennsylvania	P4	BB (65)
Mitapivat Sickle Cell Disease	Agios Pharmaceuticals, Inc.	P3	BB (65)
Montelukast Sickle Cell Disease	Great Ormond Street Hospital for Children NHS Foundation Trust	P2/3	BB (65)
Tacrolimus Sickle Cell Disease	Masonic Cancer Center, University of Minnesota	P2	BB (65)
Desferrioxamine B Sickle Cell Disease	Inova Health Care Services	P4	BB (64)
Rivaroxaban Sickle Cell Disease	University Health Network, Toronto	P3	BB (64)
Aspirin Sickle Cell Disease	Instituto Nacional de Investigacao em Saude, Angola	P3	B (63)
Autologous Cd34+ Cells Isolated From Mobilised Peripheral Blood By Positive Selection, Modified By Crispr/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-Associated Protein 9) Mediated Gene Editing Consisting Of A Guide Rna (Grna) Introduced Transiently As Ribonucleoprotein (Rnp) Complex, Targeting The Erythroid Lineage-Specific Enhancer Region Of Bcl11A (B-Cell Lymphoma/Leukemia 11A). The Site-Specific Cleavage By Cas9 Forms A Double Strand Break (Dsb), Which Is Subsequently Repaired By Nonhomologous End-Joining (Nhej), Leading To The Transcriptional Repression Of Bcl11A, A Repressor Of ?-Globin Gene Transcription Sickle Cell Disease	Vertex Pharmaceuticals Incorporated	P3	B (63)
Fludarabine Sickle Cell Disease	St. Jude Children's Research Hospital	P3	B (63)
Methotrexate Sickle Cell Disease	City of Hope Medical Center	P2	B (63)
Vitamin D Sickle Cell Disease	University of California, Davis	P2/3	B (63)
Cyclosporin A Sickle Cell Disease	City of Hope Medical Center	P2	B (62)
Melphalan Sickle Cell Disease	Emory University	P3	B (62)
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Sickle Cell Disease	University of Mississippi Medical Center	P4	B (61)
Thiotepa Sickle Cell Disease	St. Jude Children's Research Hospital	P2	B (61)
Alemtuzumab Sickle Cell Disease	St. Jude Children's Research Hospital	P3	B (60)
Deferiprone Sickle Cell Disease	Inova Health Care Services	P4	B (60)
Dynastat Sickle Cell Disease	Oman Medical Speciality Board	P3	B (60)
Etavopivat Sickle Cell Disease	Novo Nordisk A/S	P3	B (60)
L-Citrulline Sickle Cell Disease	Asklepion Pharmaceuticals, LLC	P3	B (60)
Tebapivat Sickle Cell Disease	Agios Pharmaceuticals, Inc.	P2	B (60)
Ibuprofen Sickle Cell Disease	Cairo University	P4	B (59)
Sirolimus Sickle Cell Disease	St. Jude Children's Research Hospital	P2	B (59)
Rabbit Anti-Thymocyte Globulin Sickle Cell Disease	Emory University	P2	B (58)
Rituximab Sickle Cell Disease	Columbia University	P2	B (58)
Dexasone Sickle Cell Disease	Nantes University Hospital	P3	B (57)
Ketorolac Sickle Cell Disease	Children's Blood and Cancer Center at Dell Children's Medical Center	P4	B (57)
Plerixafor Sickle Cell Disease	Hospital Israelita Albert Einstein	P2	B (57)
Voxelotor Sickle Cell Disease	Inova Health Care Services	P4	B (57)
Decitabine Sickle Cell Disease	Novo Nordisk A/S	P2	B (56)
Equine Atg Sickle Cell Disease	University of Illinois at Chicago	P2/3	B (56)
Lidocaine Sickle Cell Disease	Nantes University Hospital	P3	B (56)
Losartan Sickle Cell Disease	Children's Hospital Medical Center, Cincinnati	P2	B (56)
Meperidine Sickle Cell Disease	Nantes University Hospital	P3	B (56)
Methylphenidate Sickle Cell Disease	St. Jude Children's Research Hospital	P3	B (56)
Nexplanon Sickle Cell Disease	University of Pennsylvania	P4	B (56)
Senicapoc Sickle Cell Disease	Biossil Inc.	P3	B (56)
Zinc Sulfate Sickle Cell Disease	Indiana University	P2/3	B (56)
Crovalimab Sickle Cell Disease	Hoffmann-La Roche	P2	CCC (55)

Showing 1 to 50 of 133 assets

PreviousPage 1 of 3Next